The Tecentriq/Avastin Combo: Roche Details Renal Cell Cancer Benefits

 
• By John Davis

Roche has continued to drip-feed results from the IMmotion151 Phase III study, this time describing the magnitude of the beneficial responses observed with the first-line use of the Tecentriq-Avastin combination in patients with advanced renal cell cancer.

Kidneys
• Source: Shutterstock

More from Immuno-oncology

More from Anticancer